Indication
Refractory Renal Pelvis Urothelial Carcinoma
1 clinical trial
2 products
3 drugs
Clinical trial
A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 TherapyStatus: Recruiting, Estimated PCD: 2027-08-15
Drug
DocetaxelProduct
EribulinDrug
GemcitabineDrug
TiragolumabProduct
Sacituzumab Govitecan